AA-FENO-MICRO 67 MG
FENOFIBRATE : 67 MG · DIN 02243180 · AA PHARMA INC
Health Canada status: MARKETED
What is AA-FENO-MICRO?
AA-FENO-MICRO 67 MG contains FENOFIBRATE : 67 MG. It is listed in the Health Canada Drug Product Database under DIN 02243180, held by AA PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Nov-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AA-FENO-MICRO used for?
FENOFIBRATE (fenofibrate, non-micronized formulation) and AA-FENO-MICRO (fenofibrate, micronized formulation) are indicated as an adjunct to diet and other therapeutic measures for: 1) Treatment of patients with hypercholesterolemia, Fredrickson classification Types IIa and IIb mixed hyperlipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). 2) Treatment of adult patients with very high serum triglyceride levels, Fredrickson classification Type IV and Type V hyperlipidemias, who are at a high risk of sequelae and complications (i.e., pancreatitis) from their hyperlipidemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243180 |
|---|---|
| Brand name | AA-FENO-MICRO |
| Generic / active ingredient | FENOFIBRATE : 67 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 67 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AB05 FENOFIBRATE |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Nov-2019 |
| Original market date | 2001-02-12 00:00:00 |
How is it administered?
Micronized: 67-200 mg daily. Non-micronized: 100 mg three times daily. Administer with food. Dose reduction required in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Contraindications
Hepatic insufficiency, gallbladder disease, severe renal dysfunction, pancreatitis, hypersensitivity to fibrates, pregnancy/breastfeeding, photoallergy to fibrates, age under 18.
Warnings and precautions
Risk of myopathy/rhabdomyolysis especially with statins; liver function abnormalities (monitor AST/ALT); potential for cholelithiasis (gallstones); mild hematologic changes.
What can be used instead?
Other Canadian products sharing ATC code C10AB05 FENOFIBRATE. 10 of 56 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-FENO-MICRO | 200 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 02239864 |
| AA-FENO-SUPER | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02246859 |
| AA-FENO-SUPER | 160 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02246860 |
| LIPIDIL EZ | 145 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02269082 |
| LIPIDIL EZ | 48 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02269074 |
| LIPIDIL SUPRA | 160 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02241602 |
| SANDOZ FENOFIBRATE E | 145.0 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02390701 |
| SANDOZ FENOFIBRATE E | 48.0 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02390698 |
| SN-FENOFIBRATE E | 145 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | DIN 02454696 |
| AA-FENO-SUPER | 200 MG | TABLET | AA PHARMA INC | APPROVED | DIN 02246861 |
Who else supplies FENOFIBRATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FENOFIBRATE appears in 412 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.